MedTrace Logo

the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection

NCT04893694 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 385

Last updated 2021-08-24

No results posted yet for this study

Summary

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection

Conditions

  • SARS-CoV2 Infection

Sponsors & Collaborators

  • Ministry of Health and Population, Egypt

    collaborator OTHER_GOV

  • Fayoum University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2021-06-20
Completion
2021-07-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893694 on ClinicalTrials.gov